Esperion provides FY2024 operating expense guidance of $225M-$245M

Esperion Therapeutics, Inc.

R&D expenses expected $45M-$55M for FY2024.
SG&A expenses expected $180M-$190M for FY2024.
Total operating expenses guided at $225M-$245M.
Guidance announced at 42nd Annual J.P. Morgan Healthcare Conference on Jan 10, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Esperion Therapeutics, Inc. updated its the fiscal year ending December 31, 2024 guidance (initiated).

Period: the fiscal year ending December 31, 2024
Guidance: initiated
Result: guidance update

Exact text from the filing

Esperion Therapeutics, Inc. (the “Company”) announced in its management presentation at the 42 nd Annual J.P. Morgan Healthcare Conference the following financial guidance for the fiscal year ending December 31, 2024

View on SEC.gov

Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-001163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.